Analysis of circulating tumor DNA to confirm somatic KRAS mutations

Journal of the National Cancer Institute

Volumn 101, Issue 18, 2009, Pages 1284-1285

  Holdhoff, Matthias ^a   Schmidt, Kerstin ^a   Donehower, Ross ^a   Diaz, Luis A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; K RAS PROTEIN; DNA; GLYCINE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; VALINE;

ADULT; BLOOD ANALYSIS; CASE REPORT; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; DNA DETERMINATION; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LETTER; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCREENING TEST; SOMATIC MUTATION; TISSUE SECTION; WILD TYPE; AMINO ACID SUBSTITUTION; BLOOD; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

AMINO ACID SUBSTITUTION; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FLOW CYTOMETRY; GLYCINE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; VALINE;

EID: 70349254373     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp240     Document Type: Letter

References (7)

1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008 ; 26(10) : 1626-1634.
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 ; 359(17) : 1757-1765.
3. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009 ; 360(6) : 563-572.
4. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008 ; 14(9) : 985-990.
5. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions . Nat Methods. 2006 ; 3(7) : 551-559.
6. Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW. BEAMing up for detection and quantification of rare sequence variants. Nat Methods. 2006 ; 3(2) : 95-97.
7. Di Fiore F, Charbonnier F, Lefebure B, et al. Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer. 2008 ; 99(3) : 551-552.